Abstract
Objectives
Polyphenolic compounds are potent modulators of several pathways regulating inflammatory processes, lipid metabolism and glucose metabolism. This study aimed to explore the cardiometabolic health impacts of daily mango consumption (Mangifera indica) in individuals with overweight/obesity.
Methods
Changes in the cardiometabolic profile variables including glucose tolerance as well as physical activity habits and dietary intakes were assessed in this single-arm clinical trial of 8 men and 19 women with overweight or obesity, who consumed 280 g/day of frozen mango for 8 consecutive weeks.
Results
The intervention was not associated with significant changes in body weight, waist circumference or plasma lipid concentrations. We however noted that after consuming mangos for 8 weeks, participants showed a 3.5% reduction in systolic BP (−4.2 ± 5.8 mmHg,
P = 0.011) as well as a 10.5% reduction in 2-hour plasma glucose concentration after a 75-g oral glucose tolerance test (−0.58 ± 1.03 mmol/L, P = 0.008). When taken separately, we found that women exhibited significant decreases in systolic (−4.6 ± 5.6 mmHg, P = 0.0001) and diastolic BP (−2.6 ± 4.9 mmHg, P = 0.0322) as well as a 12.4% reduction in 2-hour plasma glucose response to the 75-g oral glucose tolerance test (−0.67 ± 1.07 mmol/L, P = 0.0134) in response to the mango consumption. Similar changes were noted in men [i.e., decreases in systolic (−3.2 ± 6.7 mmHg, P = 0.2) and diastolic BP (−4.0 ± 5.4 mmHg, P = 0.07) as well as of 2-hr plasma glucose concentrations (−0.35 ± 0.97, P = 0.3)] although these failed to reach statistical significance.
Conclusions
Our results suggest that regular mango consumption may have beneficial effects on blood pressure and glucose tolerance in individuals with overweight/obesity. Further studies need to be conducted to validate the metabolic relevance of our observations with regards to cardiometabolic health.
Funding Sources
This project was funded by the National Mango Board. JRH received postdoctoral fellowships from CIHR, INAF and NUTRISS. M-CV holds a Tier 1 Canada Research Chair in Genomics Applied to Nutrition and Metabolic Health. AM is chairholder of the Pfizer Canada – CIHR Chair in the Pathogenesis of Insulin Resistance and Cardiovascular Diseases.
Repeated Hypoglycemic Episodes with Postprandial Hyperinsulinemia after the Recovery from Acute Weight Loss Revealed by Continuous Glucose Monitoring and the Oral Glucose Tolerance Test
